Introduction: Biogen Inc. (NASDAQ: BIIB) is at a pivotal moment. A recent regulatory development – notably the review of its new Alzheimer’s drug Leqembi (lecanemab) – has the potential to significantly alter the company's outlook and investor sentiment. Biogen, a biotech focused on neurology, has seen mixed fortunes in recent years: a controversial Alzheimer’s therapy was withdrawn, while a newer Alzheimer’s treatment gained approval amid cautious uptake. This report dives into Biogen’s fundamentals – from its zero-dividend policy and debt profile to valuation metrics – and examines the key risks, red flags, and open questions that investors should weigh in light of the latest regulatory updates.
Dividend Policy & Shareholder Returns
Biogen has never paid a regular cash dividend since its inception ([1]). Management has instead preferred to reinvest earnings into R&D and strategic deals, consistent with the biotech industry’s growth-focused ethos ([2]). Because no dividend is paid, Biogen also does not offer a dividend reinvestment program ([3]). Instead, the company has returned capital to shareholders via stock buybacks. In October 2020, Biogen’s board authorized a $5 billion share repurchase program, which has no expiration date ([1]). Under this plan, Biogen bought back about 6.0 million shares for $1.8 billion in 2021 and 3.6 million shares for $750 million in 2022 ([1]). However, no shares were repurchased in 2023, as the company conserved cash – notably to fund a major acquisition that year – leaving roughly $2.1 billion still available under the buyback authorization ([1]). Biogen’s leadership periodically reviews its capital allocation strategy (including the possibility of initiating a dividend), but currently remains focused on share repurchases and business development over dividends ([1]). Investors seeking income will find Biogen’s dividend yield at 0%, and must instead look to potential stock appreciation for returns.
Leverage, Debt & Coverage
After years of relatively conservative leverage, Biogen’s debt load has increased following a recent acquisition. As of December 31, 2023, the company had $6.79 billion in long-term debt outstanding ([1]). These obligations consist primarily of unsecured senior notes maturing at various dates from 2025 through 2051, reflecting a long-term debt ladder ([1]). In 2023, Biogen borrowed additional funds to finance its $7.3 billion purchase of Reata Pharmaceuticals. It drew $1.0 billion on a term loan facility at closing, split between a 1-year $500 million tranche and a 3-year $500 million tranche ([1]). By year-end 2023, Biogen had already repaid $350 million of the short-term portion, leaving $650 million still outstanding on the term loan (with ~$150 million due within one year and $500 million due by 2026) ([1]).
Despite this uptick in debt, Biogen’s near-term maturity schedule appears manageable. Only about $400 million (including interest) was due in 2024, and roughly $2.7 billion in 2025–2026 ([1]). The bulk of Biogen’s debt—over $7 billion in obligations—is not due until 2027 and beyond, giving the company breathing room to ramp up new product revenues ([1]). Biogen also ended 2023 with about $1.0 billion in cash and marketable securities, down sharply from $5.6 billion a year prior due to the cash used for the Reata acquisition ([1]). This reduced cash cushion means Biogen now carries a net debt position, a change from its historically net-cash balance sheet.
Encouragingly, interest coverage remains strong. Biogen’s interest expense was $246.9 million in 2023 ([1]), while operating cash flow for the year was about $1.55 billion ([1]) – a comfortable 6x coverage of cash interest costs. Even on an earnings basis, the company’s EBIT far exceeds its interest obligations. Management has also undertaken cost-cutting to maintain margins: new CEO Christopher Viehbacher (appointed late 2022) initiated a $1 billion cost-savings plan in 2023 ([4]) to streamline operations as some legacy products decline. Biogen’s investment-grade credit ratings reflect its moderate leverage and robust cash flows (Moody’s rates Biogen’s senior debt Baa2, though with a currently negative outlook tied to recent debt-funded deals) ([5]). Overall, Biogen’s balance sheet leverage increased but remains at a moderate level, and interest obligations are well-covered by earnings and cash flow under current conditions.
Valuation & Peer Comparison
Biogen’s stock trades at a modest valuation relative to both the broader market and its pharma/biotech peers. As of late 2024, Biogen’s price-to-earnings ratio was in the mid-teens (about 13.7× trailing earnings) ([6]), roughly in line with other large-cap biotech companies (which often range ~13–18×) and at a discount to the overall S&P 500. On projected earnings, the multiple is even lower – Biogen’s 2025 adjusted EPS guidance ($15.25–$16.25 ([4])) implies a forward P/E around 9–10× at recent share prices, signaling a value-stock profile. Other metrics paint a similar picture. Biogen’s enterprise value is only about 2.5× its annual revenue and ~8× EBITDA, based on 2025 estimates ([7]) – a comparatively low multiple given its high-margin business. In fact, the company generated roughly $2.1 billion in free cash flow over the last 12 months (an FCF yield near 10%), with an impressive ~22% free cash flow margin ([7]). These figures underscore that the market is assigning a cautious valuation to Biogen despite its strong cash generation.
Why the low valuation? Investors appear to be balancing Biogen’s earnings power against uncertainties in its growth outlook. Unlike steady dividend-paying pharma giants, Biogen is in a transition period: revenues from its flagship multiple sclerosis (MS) franchise are declining, and its new Alzheimer’s therapy is still proving itself commercially. This contrasts with peers like Amgen or Gilead, which have broader portfolios or dividends supporting their valuations. Biogen’s valuation discount suggests skepticism about how successfully it can replace lost MS revenue – but it also could indicate upside potential if the company’s new launches outperform expectations. Notably, analysts project the total market for Alzheimer’s treatments could reach $100 billion in the coming years ([8]) given enormous unmet need. If Biogen can secure even a slice of that (through Leqembi or other pipeline drugs), current multiples might undervalue its long-term earnings power. In summary, Biogen trades cheaply relative to fundamentals, reflecting the “show me” posture of the market until key uncertainties (discussed below) are resolved.
Key Risks & Challenges
Despite its opportunities, Biogen faces several risks that investors should keep in mind:
– Declining Legacy Products: Biogen’s core MS drugs – such as Tecfidera, Avonex, and Tysabri – have been hit by generic competition and newer rival therapies. Tecfidera in particular lost exclusivity, leading to steep sales declines since 2020. In the most recent quarter, Biogen’s combined MS product revenue fell about 8% year-on-year ([4]). The company projects a mid-single-digit revenue decline in 2025 as these headwinds continue ([4]). Competition from Roche’s Ocrevus and Novartis’ Kesimpta (as well as emerging generics) is fierce ([4]). This erosion of the legacy portfolio puts pressure on Biogen to replace revenue through new products. Failure to stabilize the decline (for example, if Tysabri sales erode faster than expected or Spinraza for SMA faces more competition) would weigh on future earnings.
– Alzheimer’s Drug Uptake and Perception: Biogen’s growth hopes rest heavily on Leqembi (lecanemab), its Alzheimer’s disease treatment co-developed with Eisai. While Leqembi secured FDA approval (with full approval in July 2023) and Medicare coverage, uptake has been gradual so far ([9]). The drug’s intravenous administration and requirements for diagnostic confirmation and periodic brain scans have limited its initial rollout ([8]). Additionally, safety warnings (risk of brain swelling or bleeding known as ARIA) require careful monitoring, which can deter some physicians. Sales are growing quarter by quarter – e.g. Eisai recorded ~$67 million in global Leqembi revenue in Q3 2024 (up from $40 million in Q2) ([10]) – but this is still a small fraction of the potential patient population. There is a risk that uptake remains slower than the “blockbuster” trajectory Biogen and Eisai anticipate. Concerns over cost (about $26,500 per year) and efficacy (Leqembi slows cognitive decline but is not a cure) could limit how many patients ultimately receive it ([9]). Furthermore, regulatory scrutiny is ongoing: in Europe, officials delayed final approval to reassess safety data post-U.S. launch, causing Biogen’s stock to dip on the news ([10]) ([10]). Any unforeseen safety issues or restrictive labeling changes would pose a major setback. In short, Leqembi is a game-changer for Biogen, but its commercial success is not yet assured – and the stock’s fate is tightly linked to this outcome.
– Pipeline and R&D Setbacks: Biogen’s broader pipeline has had disappointments. Notably, its collaboration with Sage Therapeutics on depression medicine had a partial failure in 2023 – the drug zuranolone (Zurzuvae) was approved only for postpartum depression and not for the much larger indication of major depressive disorder, due to mixed trial results. This was a blow to Biogen’s diversification plans, and Sage’s stock plunged ~75% on the news ([11]). Biogen had to write down value and later offered to buy out Sage’s remaining stake for ~$469 million, an offer Sage rejected as too low ([11]). Sage instead sought other partners, leaving the future of Biogen’s role in that program uncertain. Additionally, Biogen and Sage halted development of another neuroscience drug in 2023 after a trial failure ([11]). These events underscore the risk inherent in drug development – any pipeline candidate can fail a clinical trial or get a narrow approval. Investors are particularly watching Biogen’s next Alzheimer’s candidate (an anti-tau antibody, BIIB080) and other late-stage projects in lupus and ALS. Biogen is counting on its pipeline (and newly acquired drugs like Reata’s Skyclarys for a rare neuromuscular disease) to drive growth by 2028 ([12]). If these new launches falter or face delays, Biogen could struggle to hit its long-term revenue goals.
– Competitive Pressure in Alzheimer’s: While Biogen has a head start with Leqembi, it won’t be alone in the Alzheimer’s market. Eli Lilly’s rival antibody donanemab (branded Kisunla) won FDA approval in 2024 ([13]). Like Leqembi, Lilly’s drug removes amyloid plaques and modestly slows decline. Analysts predict donanemab could generate $5 billion+ in annual sales, meaning it will share – and potentially compete for – the same patient pool as Leqembi ([14]). Lilly’s entry may intensify marketing competition but also expand the overall market through greater physician awareness and infrastructure. Biogen’s management has downplayed the threat, asserting that competition could accelerate adoption by building treatment centers and screening more patients ([8]). Nonetheless, if Lilly aggressively competes on price or convenience (donanemab has a finite dosing regimen, allowing some patients to stop therapy once plaques clear ([14])), Leqembi’s market share could be constrained. Other companies are also pursuing Alzheimer’s therapies (e.g. Roche, Acumen, and several smaller biotechs), so the field may become crowded. Biogen must execute strongly to establish Leqembi as a go-to therapy amid current and future alternatives.
– Pricing and Reimbursement Risks: High-cost drugs invite payer scrutiny. At over $25k per year, Leqembi’s price is steep for healthcare systems given potentially millions of eligible patients. U.S. Medicare has agreed to cover the drug (with requirements like patient registries), but if utilization surges, budgetary pressures could prompt tighter criteria or negotiation of rebates. Internationally, Biogen may face pushback on pricing; the European review is likely evaluating not just safety but also how to manage risk via prescribing conditions ([10]). Any restrictions, such as limiting reimbursement to certain patient subgroups, would cap sales. Moreover, political pressure on drug pricing in the U.S. remains a background risk for all pharma companies; Biogen could be affected if neurological drugs become targets for pricing reform or Medicare price negotiation in the future.
– Foreign Exchange and Macroeconomic Factors: Biogen generates a significant portion of sales overseas (for MS drugs and Spinraza), so a strong U.S. dollar has been a headwind. In 2024, currency effects trimmed revenue and profit, contributing to Biogen’s cautious outlook for 2025 ([4]). This risk will persist as long as the dollar remains elevated. Meanwhile, macroeconomic conditions (e.g. potential European recessions affecting healthcare budgets, or global supply chain issues for biologic drugs) could indirectly impact Biogen’s performance.
In summary, Biogen faces a “high-risk, high-reward” scenario. The company is navigating patent cliffs and competitive battles, even as it bets big on a new class of Alzheimer’s therapy. Successful execution could unlock significant growth, but missteps or negative surprises (clinical, commercial, or regulatory) would be detrimental given Biogen’s reliance on a few key programs.
Red Flags & Governance
Biogen has also had some red flags in its recent history, raising questions about management decisions and corporate governance:
– Aduhelm Controversy: Biogen’s saga with Aduhelm (aducanumab) – its first Alzheimer’s drug – remains a cautionary tale. The drug was approved by the FDA in 2021 under accelerated approval despite ambiguous efficacy data, leading to widespread criticism in the medical community. Biogen originally priced Aduhelm at $56,000 per year, expecting it to be a blockbuster ([15]) ([15]). Instead, doctors were largely hesitant to prescribe it due to weak evidence of benefit ([15]), and Medicare severely restricted coverage. Consequently, Aduhelm’s launch collapsed; by 2022 Biogen had all but halted marketing. In January 2024, Biogen formally decided to stop selling Aduhelm and terminate its confirmatory trial ([15]) ([15]), effectively writing off the drug. Only about 2,500 patients worldwide were on Aduhelm at the time of its discontinuation ([15]). This episode damaged Biogen’s reputation and highlighted governance concerns, as many questioned the company’s judgement in pushing Aduhelm to market and setting such a high price without solid evidence. It serves as a red flag indicating potential over-optimism by management and underscores the importance of rigorous data and transparency for shareholder trust.
– Legal/Compliance Issues: In 2022, Biogen paid $900 million to settle a whistleblower lawsuit alleging that the company illegally paid kickbacks to physicians to boost sales of its MS drugs ([16]). The case revealed that from 2009–2014, Biogen funneled payments to doctors under the guise of consulting and speaker fees, with the goal of inducing more prescriptions of Tysabri, Avonex, and Tecfidera ([16]). This large settlement – one of the biggest in the pharma industry for a kickback case – is a red flag regarding Biogen’s past sales practices and internal controls. While the alleged misconduct occurred years ago, investors must rely on Biogen’s commitment to improved compliance going forward. Any repeat of such behavior would risk heavy fines and reputational damage. It’s worth noting that Biogen’s current CEO was brought in after this era (and after Aduhelm) to help reset the company’s direction and credibility.
– Management Turnover and Strategy Shifts: The company’s recent leadership changes also bear mention. Longtime CEO Michel Vounatsos stepped down in 2022 amid the Aduhelm fallout. The new CEO, Christopher Viehbacher (former Sanofi chief), has since refocused Biogen’s strategy – emphasizing cost discipline, pipeline prioritization, and selective M&A. Viehbacher’s early moves included cutting around 1,000 jobs and implementing the $1 billion cost-saving plan ([4]), as well as the sizable Reata acquisition to bolster the rare disease portfolio ([4]). He also attempted the small Sage buyout (rebuffed by Sage’s board) and has signaled a pause on big acquisitions due to high valuations ([12]). While these actions may be positive, they also represent significant shifts. Investors should watch execution closely: large acquisitions carry integration risk, and cost cuts must not undermine R&D productivity. The fact that Biogen resorted to a major deal (Reata) suggests an acknowledgment that internal innovation alone might not fill its revenue gap – which is a yellow flag about the state of its pipeline prior to 2023. Overall, management is in rebuilding mode, and their credibility will be judged by the success of new products and the avoidance of past mistakes.
In aggregate, Biogen’s red flags highlight strategic and ethical pitfalls that the company must put behind it. There are signs of learning – e.g. Biogen has been more measured with Leqembi’s rollout and pricing ($26.5k/year, set by partner Eisai, is roughly half Aduhelm’s initial price ([14])). Still, investors will need to monitor management’s decisions (especially around drug approvals, pricing, and marketing practices) as these have clearly had material impacts on Biogen’s fortunes in the past.
Open Questions & Outlook
Looking ahead, Biogen’s investment thesis hinges on several open questions and upcoming catalysts. How these uncertainties resolve “could shift the market” for BIIB stock in one direction or the other:
– Will Leqembi Achieve its Blockbuster Potential? Biogen and Eisai believe Leqembi can become a multi-billion dollar product given the huge unmet need in early Alzheimer’s ([10]). The drug is still in the early launch phase, with U.S. sales trending upward ($39 million in Q3 2023 U.S. sales, from $30 million in Q2) ([9]). Key factors will determine its trajectory: physician confidence in the clinical benefits, the capacity of healthcare systems to diagnose and monitor patients, and patient/doctor sentiment on safety risks. An important catalyst is label and access expansion – for instance, if blood-based diagnostic tests for Alzheimer’s become widely available, it could greatly expand testing and referrals for treatment. Conversely, any safety scare or onerous monitoring requirements could dampen uptake. Outside the U.S., formal approval by the European Commission (pending the CHMP’s re-review of safety data) is expected in 2025 ([10]); a positive decision would open up another major market, while delays or conditions could slow momentum. Another upside catalyst is the potential subcutaneous formulation of Leqembi – the companies have filed with the FDA for a quicker-to-administer injection version (as maintenance therapy), with a decision expected by August 2025 ([10]). If approved, a subcutaneous Leqembi could improve convenience and adoption, allowing some patients to get treatment at home rather than infusion centers ([10]). How Leqembi’s rollout plays out over the next 1–2 years is perhaps the single biggest question for Biogen’s outlook, and investors can expect BIIB’s share price to move with each meaningful update on this front.
– How Much Will Competition Eat into the Alzheimer’s Opportunity? With Lilly’s donanemab/Kisunla now approved (and possibly others in the pipeline), the Alzheimer’s therapy market will not be Biogen’s alone. The total market could be very large – analysts see room for both drugs to each net $5 billion+ annually if broad usage is achieved ([14]). However, competition raises questions: Will Biogen be able to differentiate Leqembi on efficacy or safety? Could pricing pressures emerge if payers play the two drugs against each other for discounts? Lilly’s drug has a finite dosing regimen, which might appeal to some patients who wish to discontinue therapy after a period; Biogen’s Leqembi currently is envisioned as an ongoing treatment. On the other hand, if both drugs perform similarly, neurologists may simply have two comparable options – and the first-mover advantage could help Leqembi lock in patients. Biogen must also consider global competition: donanemab will seek approval in Europe and elsewhere, and other competitors (e.g. AC Immune’s therapeutics in trial) are on the horizon. The extent to which competition spurs faster market growth versus fragments market share remains to be seen ([8]). This balance will influence Biogen’s long-term revenue from Leqembi. An open question is also whether combination therapy (amyloid + another mechanism) will become the future standard – if so, Biogen’s own next-gen Alzheimer’s programs (like anti-tau BIIB080) could complement or protect its franchise, but if a rival develops a superior combination, Biogen could be edged out despite pioneering the space.
– Can New Products Offset Biogen’s Base Business Declines? Biogen’s CEO has boldly stated that revenue from new product launches will surpass current revenues by 2028 ([12]). “New products” include Leqembi, zuranolone (for postpartum depression), tofersen (an ALS gene therapy approved 2023), Skyclarys (Reata’s newly approved drug for Friedreich’s ataxia), and others in the late-stage pipeline. This forecast implies a return to growth after the mid-decade trough. Investors are questioning whether this is achievable. Quantitatively, Biogen’s 2022 revenue was about $10 billion – meaning new products might need to generate >$10 billion annually by 2028 to fulfill that claim, assuming the old portfolio continues shrinking. Leqembi could feasibly contribute a few billion if things go well, but what about the rest? Skyclarys serves a very small rare disease market; zuranolone (Zurzuvae) addresses postpartum depression, a limited population (and its commercialization is now primarily Sage’s responsibility, with Biogen sharing profits). Biogen does have promising neuroimmune drugs in development (e.g. for lupus and stroke), but those are unproven. Thus a critical open question is whether Biogen’s pipeline depth is sufficient to drive the next leg of growth. Pipeline execution (trial results, regulatory approvals) over 2025–2027 will heavily influence whether Biogen hits that 2028 goal. Any significant clinical successes (or failures) will be stock-moving events given the reliance on future products.
– Will Biogen Make Further Strategic Moves (M&A or Restructuring)? So far, CEO Viehbacher has indicated no urgent need for more acquisitions in the near term ([12]). Biogen will focus on integrating Reata and advancing internal R&D. However, the company’s situation could incentivize other strategic moves. One open question: Might Biogen itself become a takeover target? With a depressed valuation and coveted neuroscience assets, some analysts have speculated that a larger pharmaceutical company could consider acquiring Biogen to gain a foothold in Alzheimer’s. Though no concrete offer has emerged, this possibility cannot be ruled out if Biogen’s stock remains undervalued relative to its pipeline potential. Internally, Biogen could also consider divestitures or spin-offs (for example, its biosimilars joint venture was sold to Samsung in 2022). Thus far management hasn’t telegraphed any break-up plans, but investor pressure could mount if core growth disappoints. Another question is capital return: Will Biogen reinstate stock buybacks (or even initiate a dividend) once its cash flows improve? In 2023 the company paused repurchases to conserve cash ([1]), and it has never paid a dividend ([1]). If Leqembi and other launches start generating substantial free cash, management could decide to return more to shareholders. Such a shift in capital allocation policy would be a notable signal – either of confidence in sustained cash generation or a lack of compelling R&D investment needs – and could influence how income-focused investors view the stock.
– Execution of Cost Savings and Cultural Change: Another forward-looking consideration is whether Biogen can successfully transform itself culturally and operationally under new leadership. The cost reductions and refocusing efforts are intended to streamline the company for a new era, but they also carry execution risk. Will Biogen be able to cut costs (e.g. that $1 billion savings plan) without undermining its ability to innovate? Conversely, if sales ramp up, will it need to invest more in commercialization and infrastructure (especially for Alzheimer’s treatment delivery)? The balance between cutting fat and maintaining muscle will be critical. Additionally, after the missteps with Aduhelm and the legal issues, Biogen needs to rebuild trust with physicians, patients, and regulators. How the company handles the launch of Leqembi – responsibly educating on risks, monitoring safety, and collaborating with stakeholders – will inform its reputation. So far, the launch has been cautious and measured, which is a positive sign. Continued transparency and patient-centric behavior will be important intangible factors affecting Biogen’s long-term success.
Conclusion: Biogen today presents a complex story. The company’s fundamentals show a cash-rich business with manageable debt and a historically strong profit engine – but one that is in flux as old products wane. Valuation is undemanding, suggesting that Wall Street has modest expectations for now. This could change dramatically if Biogen proves the skeptics wrong. The latest regulatory developments, especially around Leqembi’s approvals and label updates, truly have the potential to shift the market’s view on BIIB. A smooth approval in Europe and successful adoption in the U.S. could validate Biogen’s strategic pivot to Alzheimer’s, potentially unlocking significant upside in the stock. On the other hand, any stumble – be it a safety scare, commercial shortfall, or pipeline failure – would reinforce the bear case and could keep the stock subdued.
Investors in Biogen should keep a close eye on upcoming milestones: European decisions on Leqembi (and any required safety measures), the FDA ruling on the subcutaneous formulation by late 2025 ([10]), head-to-head competitive dynamics with Lilly’s drug, and pivotal trial readouts for pipeline drugs through 2026. Biogen’s management has set an ambitious course, aiming for its “new Biogen” to outgrow the old. The next few quarters and years of execution, amid the evolving regulatory landscape, will determine if BIIB can truly shift from a turnaround story to a growth story – and in doing so, shift the market’s perception of this biotech bellwether.
Sources: Key information for this report was gathered from Biogen’s SEC filings and official investor materials, as well as reputable financial and industry news outlets. Important references include Biogen’s 2023 annual report (10-K) for financial data and policy statements ([1]) ([1]), the U.S. Department of Justice press release on the 2022 settlement ([16]), and numerous updates from Reuters, Nasdaq/Zacks, and AP covering Biogen’s product developments and forecasts ([4]) ([10]) ([15]). These sources provide a factual foundation for the analysis presented.
Sources
- https://investors.biogen.com/node/27701/html
- https://nasdaq.com/articles/3-biotechs-dont-pay-dividends-could-2016-11-22
- https://investors.biogen.com/stock-information/investor-faqs
- https://reuters.com/business/healthcare-pharmaceuticals/drugmaker-biogen-forecasts-2025-profit-below-expectations-2025-02-12/
- https://app.researchpool.com/provider/moodys-investors-service/biogen-inc-biib-moodys-affirms-biogens-baa2-rating-outlook-remains-negative-uwo0UwI1e2
- https://macrotrends.net/stocks/charts/BIIB/biogen/pe-ratio
- https://multiples.vc/public-comps/biogen-valuation-multiples
- https://reuters.com/business/healthcare-pharmaceuticals/biogen-executive-says-its-alzheimers-drug-will-do-well-market-despite-2024-06-12/
- https://reuters.com/business/healthcare-pharmaceuticals/biogen-expects-steady-growth-alzheimers-drug-leqembi-near-term-2024-12-03/
- https://nasdaq.com/articles/biogen-stock-down-regulatory-update-eu-alzheimers-drug
- https://reuters.com/markets/deals/sage-rejects-biogens-takeover-offer-explore-strategic-alternatives-2025-01-27/
- https://reuters.com/business/healthcare-pharmaceuticals/biogen-ceo-sees-no-burning-need-more-acquisitions-2025-01-14/
- https://axios.com/2024/07/02/eli-lilly-donanemab-alzheimers-fda-approval
- https://reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-lillys-alzheimers-drug-2024-07-02/
- https://thehill.com/homenews/ap/ap-business/ap-biogen-plans-to-shut-down-its-controversial-alzheimers-drug-aduhelm/
- https://fiercepharma.com/pharma/biogen-finalizes-900m-deal-settle-whistleblowers-long-running-ms-drugs-doctor-kickback-suit
For informational purposes only; not investment advice.